Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272790 | 0.90 | HDAC1 (0.54) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL273276 | 0.88 | HDAC1 (0.53) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL274664 | 0.86 | HDAC1 (0.46) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL274273 | 0.86 | HDAC1 (0.54) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL274092 | 0.85 | HDAC1 (0.47) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL272434 | 0.83 | CDK2 (0.60) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL278786 | 0.83 | CDK2 (0.61) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2638299 | 0.80 | HDAC1 (0.53) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL272800 | 0.78 | CDK2 (0.49) | KCNH2 | |
| SCHEMBL274424 | 0.76 | CDK2 (0.51) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | claimed |
| JP-2011528039-A | — | — | 2011-11-10 | — | — | JP | claimed |
| WO-2010009139-A2 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | HDAC1, CDK9, CDK2 | HDAC1 1/4885HDAC2 16/4885HDAC3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.